In June, EMA released a revised guideline covering quality issues for biosimilars using biotechnology-derived proteins. The guideline covers the quality requirements to be met when developing a biosimilar. It follows from a concept paper from 2011 and a draft from 2012. The revised version contains references to relevant guidelines that should be consulted and an expanded section on what reference products are applicable.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
